A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...

UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...

The AstraZeneca PLC ADR AZN rose 2.34% to $74.43 Wednesday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth”. The drugmaker, which is Britain’s most valuable ...

Rachel Reeves was dealt yet another blow after AstraZeneca cancelled a planned £450 million investment in a vaccine manufacturing plant. The chancellor came under fire on GB News for "making an ...

A variety of stories feature on Saturday's front pages. The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to ...

"Liverpool City Region Combined Authority has not been party to the negotiations between government and AstraZeneca, which have taken place over many months," he said. "However, we have worked ...

Finished logos can be instantly downloaded in multiple formats, such as PNG, JPG, SVG, EPS, and PDF, with transparent backgrounds and variations for digital and print use. Beyond logos, Design.com ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

While AstraZeneca confirmed no current jobs at the Speke site would be affected, the cancellation raises questions about Britain's investment climate. The Chancellor has recently attempted to shift ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...